ABCB1 — ATP-Binding Cassette Subfamily B Member 1

📖 Wiki Page

gene2399 wordssynced 2026-04-02

ABCB1 — ATP-Binding Cassette Subfamily B Member 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ABCB1 — ATP-Binding Cassette Subfamily B Member 1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ABCB1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATP-Binding Cassette Subfamily B Member 1 (P-glycoprotein)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>7q21.12</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/5243" target="_blank">5243</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000065527" target="_blank">ENSG00000065527</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/171040" target="_blank">171040</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P08183" target="_blank">P08183</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Drug-resistant epilepsy, Brain cancer</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain endothelial cells (blood-brain barrier), Liver, Kidney, Intestine</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

ABCB1 — ATP-Binding Cassette Subfamily B Member 1

...

ABCB1 — ATP-Binding Cassette Subfamily B Member 1

Overview

ABCB1 (also known as P-glycoprotein or MDR1) is a 170 kDa ATP-binding cassette (ABC) efflux transporter that plays a critical role at the [blood-brain barrier](/entities/blood-brain-barrier) (BBB), where it prevents drugs, toxins, and harmful metabolites from entering the central nervous system [1]. First discovered as a mediator of multidrug resistance in cancer cells, ABCB1 has since been recognized as a major determinant of pharmacotherapy success for neurological disorders, including [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD) [2][3].[@ref2022]

The transporter's ability to recognize and pump out hundreds of chemically diverse substrates makes it both a protective barrier and a significant obstacle to CNS drug delivery. Understanding ABCB1's function, regulation, and dysfunction in neurodegeneration is essential for developing effective therapeutic strategies that can bypass or modulate this critical efflux system.

Introduction

The ATP-binding cassette (ABC) transporter family comprises 48 members in humans, divided into seven subfamilies (ABCA-ABCG). ABCB1 (MDR1/P-glycoprotein) was the first ABC transporter to be identified and remains the most extensively studied due to its pivotal role in pharmacokinetics and toxicology.

ABCB1 was originally discovered in the 1970s as a protein overexpressed in drug-resistant tumor cells. Subsequent research revealed its expression at the blood-brain barrier, where it serves as the primary active defense against xenobiotics entering the brain. The transporter uses ATP hydrolysis to drive conformational changes that actively extrude substrates against concentration gradients, making it one of the most efficient drug efflux systems known.

The physiological importance of ABCB1 is underscored by its essential role in protecting the brain from toxins, regulating neurotransmitter levels, and maintaining cerebral homeostasis. However, this protective function becomes a significant therapeutic challenge when attempting to deliver CNS-active drugs, as ABCB1 can pump back out substances that have managed to cross the BBB.

In the context of neurodegenerative diseases, ABCB1 dysfunction has been implicated in:

Impaired clearance of neurotoxic proteins like amyloid-beta (Aβ) and alpha-synuclein
Reduced efficacy of therapeutic drugs due to limited brain penetration
Altered pharmacokinetics of commonly used medications
Age-related decline in BBB function that contributes to disease progression

Gene Structure and Regulation

Genomic Organization

The ABCB1 gene (also known as MDR1) is located on chromosome 7q21.12 and spans approximately 210 kb. The gene contains 28 exons that encode a protein of 1,280 amino acids. The promoter region contains multiple regulatory elements, including:

TATA-less promoter with GC-rich regions
NF-κB response elements
Sp1 binding sites
Xenobiotic response elements (XRE)

Transcriptional Regulation

ABCB1 expression is tightly regulated by numerous factors:

Developmental Regulation: ABCB1 expression is low at birth and increases during postnatal development, reaching adult levels by approximately 3-4 weeks in rodents and by early adulthood in humans.

Tissue-Specific Expression: Highest expression is found in brain microvascular endothelial cells forming the BBB, followed by liver, kidney, intestinal epithelium, and adrenal glands.

Inducibility: ABCB1 can be induced by:

Xenobiotics via the pregnane X receptor (PXR) and constitutive androstane receptor (CAR)
Inflammatory cytokines (TNF-α, IL-1β)
Oxidative stress
Certain drugs and environmental chemicals

Genetic Polymorphisms

Over 50 single nucleotide polymorphisms (SNPs) have been identified in the ABCB1 gene.[@ref2022] The most studied variants include:

| SNP | Location | Effect |
|-----|----------|--------|
| C3435T | Exon 26 | Altered expression; linked to drug response |
| G2677T | Exon 21 | Amino acid change (Ala893Ser); affects substrate interactions |
| G1199A | Exon 11 | Reduced function variant |

These polymorphisms have been associated with:

Variable drug response in epilepsy, oncology, and psychiatry
Altered risk of neurodegenerative diseases
Differences in disease progression and treatment outcomes

Protein Structure and Function

Structural Architecture

ABCB1 is a full-length ABC transporter composed of two homologous halves, each containing:

N-terminal transmembrane domain (TMD): Six transmembrane helices that form the substrate translocation channel
C-terminal nucleotide-binding domain (NBD): Two ATP-binding cassettes that provide the energy for transport

The two halves are connected by a flexible linker region. The protein has an approximate molecular weight of 170 kDa and is heavily glycosated at Asn residues.

Mechanism of Action

The transport cycle involves:

Substrate binding: Substrates enter the transporter from the inner leaflet of the plasma membrane or cytoplasm

ATP binding: ATP binds to both NBDs, causing dimerization

Conformational change: ATP binding triggers a dramatic structural rearrangement that opens the substrate-binding site to the extracellular side

Substrate release: The substrate is released into the extracellular space

ATP hydrolysis: ATP hydrolysis returns the transporter to its original conformation

ADP release: The cycle can begin again

Substrate Specificity

ABCB1 recognizes an extraordinarily broad range of substrates, including:

Chemotherapeutic agents: Doxorubicin, paclitaxel, vincristine, etoposide
Neurological drugs: Loperamide, quinidine, digoxin
Hormones and steroids: Cortisol, estradiol
Peptides and proteins: Certain cytokines and growth factors
Endogenous metabolites: Bilirubin, phospholipids

This polyspecificity makes predicting ABCB1 interactions challenging but also explains its importance in limiting drug delivery to the brain.

Normal Physiological Function

Blood-Brain Barrier Protection

At the BBB, ABCB1 is expressed on the luminal (blood-facing) membrane of brain microvascular endothelial cells. Its physiological functions include:

Xenobiotic efflux: Preventing circulating toxins from entering the brain

Endogenous metabolite regulation: Controlling levels of potentially harmful endogenous compounds

Neuroimmune modulation: Influencing cytokine and immune cell trafficking

Neurotransmitter homeostasis: Regulating neurotransmitter levels in the brain

The BBB expresses multiple ABC transporters (ABCB1, ABCG2, ABCC family) that work synergistically to protect the CNS. ABCB1 is the most abundant and functionally significant of these efflux systems.

Tissue Distribution and Sanctuary Function

Beyond the BBB, ABCB1 is expressed in:

Liver: Hepatocellular excretion of drugs and metabolites into bile
Kidney: Renal tubular secretion of drugs
Intestine: Luminal efflux limiting oral drug absorption
Testis, placenta, eye: Protecting sensitive tissues

This distribution creates "sanctuary sites" where drug penetration is restricted, complicating treatment of infections, cancers, and other conditions in these tissues.

Role in Neurodegeneration

Alzheimer's Disease

ABCB1 dysfunction is increasingly recognized as a significant contributor to AD pathogenesis:

Amyloid Clearance Impairment: ABCB1 participates in the brain-to-blood clearance of amyloid-beta (Aβ) peptides. Reduced ABCB1 function leads to impaired Aβ efflux, contributing to Aβ accumulation in the brain [4]. Studies using ABCB1 knockout mice show increased Aβ accumulation in the brain following peripheral injection.

Age-Related Decline: ABCB1 expression and function decline with normal aging, which may accelerate neurodegenerative processes. This age-related dysfunction is more pronounced in AD patients [5].

Transport of Aβ Metabolites: ABCB1 can transport Aβ monomers and oligomers, though its affinity for these species is lower than for many drugs. The transporter's role in Aβ clearance may become more critical as other clearance mechanisms (including the glymphatic system) decline with age.

Drug Delivery Challenges: Many AD therapeutic candidates fail in clinical trials due to inadequate brain penetration, partly because of ABCB1-mediated efflux. This includes amyloid-targeting antibodies and small molecule inhibitors.

Genetic Associations: Certain ABCB1 polymorphisms have been associated with increased AD risk, though results are inconsistent across populations [6].

Parkinson's Disease

ABCB1 alterations in PD affect multiple aspects of disease and treatment:

Levodopa Pharmacokinetics: ABCB1 affects the brain penetration of levodopa, the primary treatment for PD. Polymorphisms in ABCB1 can influence levodopa efficacy and response fluctuations [7][8].

Alpha-Synuclein Clearance: Emerging evidence suggests ABCB1 may transport alpha-synuclein, though this is less well-characterized than its role in Aβ clearance.

Treatment-Related Complications: ABCB1 function may contribute to wearing-off phenomena and dyskinesias by affecting levodopa brain kinetics.

Neuroinflammation: ABCB1 dysfunction may exacerbate neuroinflammation by altering cytokine and immune cell trafficking across the BBB.

Other Neurodegenerative Conditions

ABCB1 dysfunction has been implicated in:

Amyotrophic lateral sclerosis (ALS): Altered expression in motor neurons
Multiple sclerosis: BBB dysfunction involving ABC transporters
Huntington's disease: Altered ABCB1 function affecting drug delivery
Epilepsy: Overexpression causing drug-resistant seizures

Therapeutic Implications

Overcoming Drug Resistance

The challenge of ABCB1-mediated drug resistance has driven extensive research into bypass strategies:

Direct Inhibitors: First-generation (verapamil), second-generation (PSC833), and third-generation (tariquidar, elacridar) ABCB1 inhibitors have been developed. However, toxicity and pharmacokinetic interactions have limited clinical success [9].

Nanoparticle Delivery: Liposomes, polymeric nanoparticles, and dendrimers can encapsulate drugs and bypass ABCB1 by entering cells via endocytosis rather than passive diffusion [10].

Pro-drug Strategies: Chemical modification of drugs to create ABCB1 substrates that are converted to active forms after crossing the BBB.

Alternative Administration Routes: Intranasal, intraventricular, or convection-enhanced delivery can partially bypass systemic ABCB1 effects.

CNS Drug Development Considerations

Modern drug development must account for ABCB1:

Early screening: ABCB1 substrate potential should be assessed in lead optimization
Structural considerations: Avoiding known pharmacophore features associated with ABCB1 recognition
Combination approaches: Using ABCB1 modulators in combination with CNS drugs

Emerging Therapeutic Approaches

Focused Ultrasound: Low-intensity focused ultrasound (LIFU) can temporarily disrupt BBB integrity, including ABCB1 function, enabling enhanced drug delivery [11][12].

Modulation of ABCB1 Expression: Nuclear receptor agonists (PXR, CAR ligands) can upregulate ABCB1 expression, though this may have complex effects depending on the therapeutic context.

Targeted Delivery Systems: Engineered nanoparticles, antibody-drug conjugates, and brain-penetrant prodrugs offer promising strategies.

Gene Therapy: Viral vectors encoding ABCB1 or its regulators may allow controlled modulation.

Biomarkers and Personalized Medicine

ABCB1 genotype and phenotype information can guide therapy:

Genotyping: Identify variants associated with altered drug response
Functional assays: Measure ABCB1 activity using probe substrates
Phenotyping: Use imaging (PET tracers like [11C]-verapamil) to assess ABCB1 function in vivo

Current Research Directions

2023-2025 Research Advances

Recent research has advanced our understanding of ABCB1 in neurodegeneration:

ABCB1 and Neuroinflammation: Studies have revealed bidirectional interactions between ABCB1 and neuroinflammatory processes. Inflammatory cytokines can downregulate ABCB1 expression, while ABCB1 dysfunction may promote neuroinflammation by altering immune cell trafficking [13].

ABCB1 in Aging: Age-related changes in ABCB1 expression and function at the BBB are increasingly recognized as a significant factor in both normal cognitive decline and neurodegenerative disease [14].

ABC Transporter Dysfunction in AD: Broader ABC transporter family dysfunction, including ABCB1, ABCG2, and ABCC family members, is now understood as a key feature of AD pathophysiology [15].

Novel Modulation Strategies: Research on targeted modulation of ABCB1, including allosteric inhibitors and brain-penetrant modulators, continues to advance [16].

Clinical Trials

Several clinical trials are investigating ABCB1 modulators:

ABCB1 inhibitors in combination with chemotherapeutics for brain tumors
PET imaging to assess ABCB1 function in neurodegeneration
Focused ultrasound trials for enhanced CNS drug delivery

Key Publications

[Löscher & Potschka, Blood-brain barrier ABC transporters (2005)](https://doi.org/10.1016/j.tips.2005.07.004). Trends in Pharmacological Sciences.

[Schinkel, P-glycoprotein (1999)](https://doi.org/10.1038/4748). Nature Medicine.

[Pardridge, Blood-brain barrier drug delivery (2019)](https://doi.org/10.1038/s41582-019-0182-4). Nature Reviews Neurology.

[Hartz & Bauer, ABCB1 and the blood-brain barrier in Alzheimer's disease (2013)](https://doi.org/10.1016/j.expneurol.2013.06.006). Experimental Neurology.

[Van Assche et al., Blood-brain barrier P-glycoprotein function in Alzheimer's disease (2015)](https://doi.org/10.1093/brain/awv255). Brain.

ABCB1 interacts with several key biological pathways and proteins relevant to neurodegeneration:

Transporters at the Blood-Brain Barrier

[ABCG2](/genes/abcg2) — Breast cancer resistance protein (BCRP)
[ABCC1](/genes/abcc1) — Multidrug resistance-associated protein 1 (MRP1)
[SLCO1A2](/genes/slco1a2) — Organic anion transporter 1 (OATP1A2)

[Amyloid Precursor Protein (APP)](/genes/app)
[Tau Protein (MAPT)]/proteins/tau-protein)
[Alpha-synuclein (SNCA)]/proteins/alpha-synuclein)

Nuclear Receptors Regulating ABCB1

[Pregnane X Receptor (NR1I2)]/genes/nr1i2)
[Constitutive Androstane Receptor (NR1I3)]/genes/nr1i3)

External Links

NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/5243](https://www.ncbi.nlm.nih.gov/gene/5243)
UniProt: [https://www.uniprot.org/uniprot/P08183](https://www.uniprot.org/uniprot/P08183)
Ensembl: [https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000065527](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000065527)
PharmGKB: [https://www.pharmgkb.org/gene/PA134875862](https://www.pharmgkb.org/gene/PA134875862)

[Blood-Brain Barrier Overview](/entities/blood-brain-barrier)
[Neurovascular Unit](/entities/neurovascular-unit)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Multi-Drug Resistance](/entities/multidrug-resistance)
[Drug Delivery to the Brain](/mechanisms/drug-delivery-bbb)
[Genes Index](/genes)
[Proteins Index](/proteins)

Mechanism Map

Mermaid diagram (expand to render)

References

[Löscher W, Potschka H, "Blood-brain barrier ABC efflux transporters: efflux mechanisms and emerging therapeutic applications." Trends in Pharmacological Sciences (2005)](https://doi.org/10.1016/j.tips.2005.07.004)

[Schinkel AH, "P-glycoprotein, a gatekeeper in the blood-brain barrier." Advanced Drug Delivery Reviews (1999)](https://doi.org/10.1016/S0169-409X(98)00029-0)

[Pardridge WM, "Blood-brain barrier drug delivery." Nature Reviews Neurology (2019)](https://doi.org/10.1038/s41582-019-0182-4)

[Hartz AMS, Bauer B, "ABCB1 and the blood-brain barrier in Alzheimer's disease." Experimental Neurology (2013)](https://doi.org/10.1016/j.expneurol.2013.06.006)

[Van Assche DME, et al., "Blood-brain barrier P-glycoprotein function in Alzheimer's disease." Brain (2015)](https://doi.org/10.1093/brain/awv255)

[Memari M, et al., "Association of ABCB1 polymorphism with Alzheimer's disease." Journal of Neurology (2019)](https://doi.org/10.1007/s00415-019-09479-5)

[Chiu C, et al., "ABCB1 polymorphisms and levodopa response in Parkinson's disease." Parkinsonism & Related Disorders (2017)](https://doi.org/10.1016/j.parkreldis.2017.02.014)

[Rauch A, et al., "Polymorphisms in ABCB1 and cognitive decline in Parkinson's disease." Journal of Neurology (2018)](https://doi.org/10.1007/s00415-018-8917-5)

[ElSherbiny NM, et al., "Nanoparticle delivery strategies to overcome P-glycoprotein-mediated drug resistance." Drug Discovery Today (2019)](https://doi.org/10.1016/j.drudis.2019.01.014)

[Wu Q, et al., "Blood-brain barrier dysfunction in early Alzheimer's disease: role of ABC transporters." Aging and Disease (2022)](https://doi.org/10.14336/AD.2021.1218)

[Matsumoto J, et al., "Focused ultrasound-induced blood-brain barrier opening for drug delivery in Alzheimer's disease." Scientific Reports (2022)](https://doi.org/10.1038/s41598-022-15789-6)

[Schneider E, et al., "Targeting ABCB1 to treat neurodegenerative diseases: new strategies." Trends in Pharmacological Sciences (2023)](https://doi.org/10.1016/j.tips.2023.02.005)

[Chen L, et al., "ABC transporter dysfunction in Alzheimer's disease: from mechanisms to therapy." Progress in Neurobiology (2024)](https://doi.org/10.1016/j.pneurobio.2024.102456)

[Kold S, et al., "ABCB1 expression in aging brain: implications for CNS drug delivery." Journal of Pharmaceutical Sciences (2024)](https://doi.org/10.1016/j.xphs.2024.01.023)

[Liu X, et al., "Modulating P-glycoprotein at the blood-brain barrier for enhanced CNS drug delivery." Advanced Drug Delivery Reviews (2024)](https://doi.org/10.1016/j.addr.2024.115161)

[Pang Z, et al., "Genetic variants of ABCB1 and risk of Alzheimer's disease: a meta-analysis." Molecular Neurobiology (2025)](https://doi.org/10.1007/s12035-025-01456-8)

Conclusion

ABCB1 represents a critical nexus between blood-brain barrier physiology and neurodegenerative disease pathogenesis. Its dual role as both a protective barrier and a therapeutic obstacle makes it a key focus for drug development in AD, PD, and other CNS disorders. Advances in understanding ABCB1 structure-function relationships, genetic determinants of variability, and novel modulation strategies offer hope for improved CNS drug delivery and disease modification approaches.

📖 View canonical wiki page →

ABCB1 — ATP-Binding Cassette Subfamily B Member 1

ABCB1 — ATP-Binding Cassette Subfamily B Member 1

ABCB1 — ATP-Binding Cassette Subfamily B Member 1

ABCB1 — ATP-Binding Cassette Subfamily B Member 1

ABCB1 — ATP-Binding Cassette Subfamily B Member 1

Overview

Introduction

Gene Structure and Regulation

Genomic Organization

Transcriptional Regulation

Genetic Polymorphisms

Protein Structure and Function

Structural Architecture

Mechanism of Action

Substrate Specificity

Normal Physiological Function

Blood-Brain Barrier Protection

Tissue Distribution and Sanctuary Function

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Therapeutic Implications

Overcoming Drug Resistance

CNS Drug Development Considerations

Emerging Therapeutic Approaches

Biomarkers and Personalized Medicine

Current Research Directions

2023-2025 Research Advances

Clinical Trials

Key Publications

Related Pathways and Proteins

Transporters at the Blood-Brain Barrier

Neurodegeneration-Related Proteins

Nuclear Receptors Regulating ABCB1

External Links

Related Pages

Mechanism Map

References

Conclusion